Clinical Trial

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2015-04-08; most recent amendment 2022-09-09.
Status change: Recruiting → Active, Not Recruiting 2017-10-25
Status change: Not Yet Recruiting → Recruiting 2015-10-12
Trial Details
NCT Number NCT02415413
Lead Sponsor PETHEMA Foundation
Collaborators: Celgene Corporation, Amgen
Conditions Smoldering Multiple Myeloma
Enrollment 90 participants
Start Date 2015-05
Primary Completion 2018-07-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2022-09-10